SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members rally around anticipation of a major upcoming partnership announcement, widely speculated to involve Ripple or XRP, alongside excitement over its new global stablecoin payroll integration with Stellar. While some investors focus on long-term utility and potential listings on major exchanges, community discourse remains polarized between optimistic holders eyeing generational wealth and skeptics dismissing recent price action as a pump-and-dump cycle.

Maul Coin

Maul Coin is trending as the community actively coordinates to push the token's visibility on social platforms and trading sites, fueled by an active developer and hopes of reaching higher market caps. While enthusiasts celebrate its organic growth and community-driven approach, skeptics remain vocal about concerns regarding potential volatility, lack of a chart, and typical risks associated with low-cap crypto projects.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is capturing significant trader attention as a high-performance Layer 1 blockchain, with the community actively debating its potential to rival existing networks through speed and parallel processing. While price action has seen volatility alongside broader crypto market trends, discussions are heavily focused on long-term accumulation, staking rewards, and anticipation of upcoming ecosystem developments.

Monero

Monero is seeing heightened activity as community members debate its status as the leading privacy-focused asset amid ongoing regulatory scrutiny and discussions regarding its long-term viability as a secure alternative to more transparent cryptocurrencies. Enthusiasts are actively comparing its unique privacy features to other assets, frequently highlighting its role in personal financial sovereignty while tracking its performance through market volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently facing significant downward pressure and investor frustration, with the community actively debating whether the stock is a long-term 'holy grail' opportunity or a failing venture as it sits at a critical technical support level. Investors remain highly focused on upcoming manufacturing milestones and the potential for a short squeeze, while sentiment is polarized between those accumulating shares for a multi-year horizon and others disillusioned by the lack of immediate commercial catalysts.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the project's longevity and humorous branding, actively promoting the token's presence across major platforms and cross-promoting with other popular assets. Enthusiasts are focused on organic growth and widespread adoption, frequently engaging with the community through social memes and dedicated poker events.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently experiencing significant market movement and high volume driven by intense community speculation regarding a potential buyout or M&A activity. The stock has seen unusual after-hours trading and sustained call option accumulation, leading investors to closely monitor for official announcements or catalyst-driven price volatility.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense social media discussion as the community debates its valuation and high price-to-earnings ratio ahead of its earnings release. While some investors remain cautious about margin pressures and the macro environment, others are highlighting strong unit-level economics, rapid store expansion, and high customer loyalty as reasons to hold the stock through the uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>XTL will acquire NeuroNOS for 19.9% of its issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million. &nbsp;</li><li>NeuroNOS is a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD) and other neurodevelopmental and neurodegenerative disorders.&nbsp;</li><li>NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.</li></ul>Shares of Beyond Air, Inc. (XAIR) rallied 149% on Tuesday after XTL Biopharmaceuticals Ltd. (XTLB) announced a deal to acquire a majority stake in its subsidiary NeuroNOS Ltd.Under the deal, IP portfolio company XTL will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.beyondair.net/news-events/press-releases?i=161064">acquire</a> 85% of NeuroNOS, a biotechnology company eyeing the development of therapeutics for Autism Spectrum Disorder (ASD), and other neurodevelopmental and neurodegenerative disorders.Shares of XTLB gained 51% at the time of writing.<h2 class="st-heading-2">Deal Terms</h2>As part of the deal, XTL will acquire 85% of NeuroNOS for 19.9% of XTL's issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million.XTL noted that NeuroNOS's drug development platform is designed to address the underlying molecular mechanisms driving autism unlike treatments based on behavioral symptoms. NeuroNOS will now serve as XTL's platform for autism and neuro-oncology therapeutics.According to BeyondAir, autism spectrum disorder affects about one in 31 children in the U.S. and has been rising dramatically. No FDA-approved therapies aimed at disease modification exist for the disorder at present.The company also noted that the Trump administration has, in recent times, emphasized support for new medicines aimed at treating autism.“The administration has allocated $50 million in new NIH funding for autism research initiatives. This recognition at the federal level signals a fundamental shift in regulatory priorities and resource allocation toward autism research and treatment development,” BeyondAir said in a statement.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around XAIR and XTLB rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user applauded the deal, opining that selling most of the unit will help de-risk Beyond Air’s investment while also creating potential future revenue streams.<stembedurl>https://www.stocktwits.com/stockpro2010/message/641694012</stembedurl><a href="https://stocktwits.com/symbol/XAIR">XAIR stock</a> has fallen 70% this year while <a href="https://stocktwits.com/symbol/XTLB">XTLB</a> dropped 44% in the same period.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/travere-therapeutics-stock-slumps-after-fda-extends-drug-review-timeline-to-april/cmUXhZuR4IK">Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

XAIR Stock More Than Doubled Today — What’s Driving The Rally?

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.

Equity

Beyond Air said that IP portfolio company XTL will acquire 85% of its subsidiary NeuroNOS.


CommScope Holding Company Inc. (COMM) witnessed retail sentiment and message volume hit a one-year high on Stocktwits on Monday after the company struck a deal to divest its Connectivity and Cable Solutions (CCS) division to Amphenol Corporation (APH) in an all-cash transaction valued at $10.5 billion.&nbsp;The transaction is slated to close in the first half of 2026, pending shareholder approval and regulatory clearance.&nbsp;<a href="https://stocktwits.com/symbol/COMM">CommScope stock</a> traded over 91% higher by Monday afternoon. Retail sentiment around the stock shifted to ‘extremely bullish’ (98/100) from ‘bullish’ territory the previous day. Message volume jumped to ‘extremely high’ (96/100) from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:953/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_135903_png_0a79ce6cc2.webp" alt="COMM’s Sentiment Meter and Message Volume as of 02:00 p.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="953" height="104"><figcaption>COMM’s Sentiment Meter and Message Volume as of 02:00 p.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user lauded the buyout.&nbsp;<stembedurl>https://stocktwits.com/ghcb1981/message/623597970</stembedurl>Another user expects the stock to finish above $15, saying ‘Get in while it’s cheap!’<stembedurl>https://stocktwits.com/SvenneKaare/message/623621273</stembedurl>The agreement marks a major reshaping of CommScope’s business portfolio as it focuses on core operations. The company anticipates net proceeds of roughly $10 billion once taxes and fees are accounted for, and a significant portion will go toward paying off all existing debt and redeeming its preferred shares, currently held by The Carlyle Group Inc. (CG).&nbsp;The company noted it will retain some leverage on its remaining operations but expects to hold a substantial cash reserve after the transaction.Once the sale is completed and all financial obligations are settled, CommScope intends to return surplus funds to investors. A dividend distribution is expected within 60 to 90 days of closing, though final details, including the exact payout, will be determined later.The company also reported its second-quarter (Q2) revenue of $1.39 billion, beating the analysts’ consensus estimate of $1.25 billion, as per Fiscal AI data. CommScope stock has gained over 188% year-to-date and over 643% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-s-podcast-bet-falters/chrXAm9Rdcb">Amazon’s Podcast Bet Falters As Job Cuts Loom At Wondery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo for Commscope is displayed during the Tech Show at ExCel London on March 12, 2025 in London, England.

CommScope Stock Rockets 91% As Retail Bulls Cheer $10.5B Asset Sale: ‘Get In While It’s Cheap!’

Once the sale is completed and all financial obligations are settled, CommScope intends to return surplus funds to investors. 

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

X.T.L. Biopharmaceuticals Ltd. - ADR

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$2.43
Prev Close	$2.45
Open	$2.47
Dividend Yield	N/A
50-Day Moving Average	$3.12
Beta	0.48
Avg. Volume	9,174.17
PE Ratio	N/A

52-Week High	$10.28
52-Week Low	$2.12
Market Capitalization	$5.75M
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

XTLB
XTL Biopharmaceuticals Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest XTLB News

XTLBXTL Biopharmaceuticals Ltd.